The risk of venous thromboembolism (VTE) in cancer patients is significantly increased, which seriously affects the quality of life and prognosis of patients. In recent years, the role of traditional Chinese medicine in the prevention of VTE in cancer patients has attracted increasing attention. This article comprehensively analyzed the relevant literature, and deeply discussed the mechanism of action, clinical application and research progress of traditional Chinese medicine in preventing VTE in cancer patients. Studies have shown that traditional Chinese medicine can prevent VTE by improving blood circulation, inhibiting platelet aggregation, promoting the activity of fibrinolytic system, inhibiting the procoagulant activity of tumor cells, protecting vascular endothelial cells, etc. However, there are still some problems that need to be further solved, such as the lack of large-scale, multi-center clinical trials, the mechanism of action is not fully clear, and the difficulty of quality control of traditional Chinese medicine. In the future, more high-quality studies are needed to provide more sufficient evidence for the clinical rational use of traditional Chinese medicine to prevent VTE in cancer patients.

1.Khorana AA, Mackman N, Falanga A, et al. Cancer-associated venous thromboembolism[J]. Nat Rev Dis Primers, 2022, 8(1): 11. DOI: 10.1038/s41572-022-00336-y.

2.Pedersen S, Kristensen AF, Falkmer U, et al. Increased activity of procoagulant factors in patients with small cell lung cancer[J]. PLoS One, 2021, 16(7): e0253613. DOI: 10.1371/journal.pone.0253613.

3.Connolly GC, Phipps RP, Francis CW. Platelets and cancer-associated thrombosis[J]. Semin Oncol, 2014, 41(3): 302-310. DOI: 10.1053/j.seminoncol.2014.04.009.

4.Yates CM, McGettrick HM, Nash GB, et al. Adhesion of tumor cells to matrices and endothelium[J]. Methods Mol Biol, 2014, (1070): 57-75. DOI: 10.1007/978-1-4614-8244-4_5.

5.Wei Q, Wei ZQ, Jing CQ, et al. Incidence, prevention, risk factors, and prediction of venous thromboembolism in Chinese patients after colorectal cancer surgery: a prospective, multicenter cohort study[J]. Int J Surg, 2023, 109(10): 3003-3012. DOI: 10.1097/JS9.0000000000000553.

6.Mitani A, Jo T, Yasunaga H, et al. Venous thromboembolic events in patients with lung cancer treated with cisplatin-based versus carboplatin/nedaplatin-based chemotherapy[J]. Anticancer Drugs, 2018, 29(6): 560-564. DOI: 10.1097/CAD.0000000000000625.

7.Daguenet E, Maison M, Tinquaut F, et al. Venous thromboembolism and radiation therapy: The final radiation-induced thrombosis study analysis[J]. Cancer Med, 2022, 11(8): 1753-1762. DOI: 10.1002/cam4.4559.

8.Curigliano G, Balduzzi A, Cardillo A, et al. Low-dose aspirin for the prevention of venous thromboembolism in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheter[J]. Support Care Cancer, 2007, 15(10): 1213-1217. DOI: 10.1007/s00520-007-0277-0.

9.Méan M, Breakey N, Stalder O, et al. Thrombophilia and outcomes of venous thromboembolism in older patients[J]. Res Pract Thromb Haemost, 2022, 16, 7(1): 100015.DOI: 10.1016/j.rpth.2022.100015.

10.Leong CH, Ranjan SR, Javed A, et al. Predictive accuracy of boosted regression model in estimating risk of venous thromboembolism following minimally invasive radical surgery in pharmacological prophylaxis-naïve men with prostate cancer[J]. World J Surg Oncol, 2024, 22(1): 67. DOI: 10.1186/s12957-023-03170-y.

11.Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis[J]. Blood, 2002, 100(10): 3484-3488. DOI: 10.1182/blood-2002-01-0108.

12.Zhang Y, Yang Y, Chen W, et al. Hypertension associated with venous thromboembolism in patients with newly diagnosed lung cancer[J]. Sci Rep, 2016, 22(6): 19603. DOI: 10.1038/srep19603.

13.Wei B, Sun C, Wan H, et al. Bioactive components and molecular mechanisms of Salvia miltiorrhiza Bunge in promoting blood circulation to remove blood stasis[J]. J Ethnopharmacol, 2023, 317: 116697. DOI: 10.1016/j.jep.2023.116697.

14.Maione F, De Feo V, Caiazzo E, et al. Tanshinone IIA, a major component of Salvia milthorriza Bunge, inhibits platelet activation via Erk-2 signaling pathwayr[J]. J Ethnopharmacol, 2014, 155(2): 1236-1242. DOI: 10.1016/j.jep.2014.07.010.

15.Shao H, He X, Zhang L, et al. Efficacy of ligustrazine injection as adjunctive therapy in treating acute cerebral infarction: a systematic review and meta-analysis[J]. Front Pharmacol, 2021, 12: 761722. DOI: 10.3389/fphar.2021.761722.

16.Wang Z, Liu Z, Zhou L, et al. Immunomodulatory effect of APS and PSP is mediated by Ca2+-cAMP and TLR4/NF-κB signaling pathway in macrophage[J]. Int J Biol Macromol, 2017, 94(PtA): 283-289. DOI: 10.1016/j.ijbiomac.2016.10.018.

17.谢雯, 吴健鸿. 黄芪多糖对慢性血栓栓塞性肺动脉高压大鼠的抗血栓保护作用[J]. 今日药学, 2023, 33(8): 586-591. [Xie W, Wu JH. Antithromboprotective effects of astragalus polysaccharide in chronic thromboembolic pulmonary hypertension rats[J]. Today's Pharmacology, 2023, 33(8): 586-591.] DOI: 10.12048/j.issn.1674-229X.2023.08.004.

18.Chang GT, Kang SK, Kim JH, et al. Inhibitory effect of the Korean herbal medicine, Dae-Jo-Whan, on platelet-activating factor-induced platelet aggregation[J]. J Ethnopharmacol, 2005, 102(3): 430-439. DOI: 10.1016/j.jep.2005.07.003.

19.Han Y, Chen Y, Zhang Q, et al. Overview of therapeutic potentiality of Angelica sinensis for ischemic stroke[J]. Phytomedicine, 2021, 90: 153652. DOI: 10.1016/j.phymed.2021.153652.

20.Wang KY, Tull L, Cooper E, et al. Recombinant protein production of earthworm lumbrokinase for potential antithrombotic application[J]. Evid Based Complement Alternat Med, 2013, 2013: 783971. DOI: 10.1155/2013/783971.

21.吴青松, 巨少华, 周凌, 等. 水蛭联合全蝎冻干粉对大鼠颈动脉血栓形成及凝血功能和纤溶系统的影响[J]. 中国现代应用药学, 2024, 41(5): 644-648. [Wu QS, Ju SH, Zhou L, et al. Effects of leech combined with freeze-dried powder of whole scorpion on carotid artery thrombosis, coagulation function and fibrinolytic system in rats[J]. Modern Applied Pharmacology of China, 2024, 41(5): 644-648.] DOI: 10.13748/j.cnki.issn1007-7693.20222461.

22.毛文娟, 么杨, 秦文杰. 复方苦参注射液联合吉非替尼对晚期非小细胞肺腺癌患者高凝状态的影响研究[J].中国医院用药评价与分析, 2022, 22(11): 1330-1333. [Mao WJ, Mu Y, Qin  WJ. Effect of compound bitter ginseng injection combined with gefitinib on hypercoagulability in patients with advanced non-small cell lung adenocarcinoma[J]. China Hospital Drug Evaluation and Analysis, 2022, 22(11): 1330-1333.] DOI: 10.14009/j.issn.1672-2124.2022.11.011.

23.Kim DC, Ku SK, Bae JS. Anticoagulant activities of curcumin and its derivative[J]. BMB Rep, 2012, 45(4): 221-226. DOI: 10.5483/bmbrep.2012.45.4.221.

24.Chen Q, Xu Q, Zhu H, et al. Salvianolic acid B promotes angiogenesis and inhibits cardiomyocyte apoptosis by regulating autophagy in myocardial ischemia[J]. Chin Med, 2023, 18(1): 155. DOI: 10.1186/s13020-023-00859-w.

25.Hu Q, Zhang W, Wu Z, et al. Baicalin and the liver-gut system: pharmacological bases explaining its therapeutic effects[J]. Pharmacol Res, 2021, 165: 105444. DOI: 10.1016/j.phrs.2021.105444.

26.Zhang Q, Liu J, Duan H, et al. Activation of Nrf2/HO-1 signaling: an important molecular mechanism of herbal medicine in the treatment of atherosclerosis via the protection of vascular endothelial cells from oxidative stress[J]. J Adv Res, 2021, 34: 43-63. DOI: 10.1016/j.jare.2021.06.023.

27.Wang YL, Zhang Q, Yin SJ, et al. Screening of blood-activating active components from Danshen-Honghua herbal pair by spectrum-effect relationship analysis[J]. Phytomedicine, 2019, 54: 149-158. DOI: 10.1016/j.phymed.2018.09.176.

28.Huang S, Chen J, Liu X, et al. Evaluation of the pharmaceutical activities of chuanxiong, a key medicinal material in traditional Chinese medicine[J]. Pharmaceuticals (Basel), 2024, 17(9): 1157. DOI: 10.3390/ph17091157.

29.Shen J, Zeng L, Pan L, et al. Tetramethylpyrazine regulates breast cancer cell viability, migration, invasion and apoptosis by affecting the activity of Akt and caspase-3[J]. Oncol Lett, 2018, 15(4): 4557-4563. DOI: 10.3892/ol.2018.7851.

30.周美丽, 韩妮萍. 当归的有效成分及药理作用研究进展[J]. 环球中医药, 2024, 17(7): 1420-1427. [Zhou ML, Han NP. Progress of research on the active ingredients and pharmacological effects of Angelica sinensis[J]. Global Chinese Medicine, 2024, 17(7): 1420-1427.] DOI: 10.3969/j.issn.1674-1749.2024.07.038..

31.Li HX, Han SY, Wang XW, et al. Effect of the carthamins yellow from carthamus tinctorius L. on hemorheological disorders of blood stasis in rats[J]. Food Chem Toxicol, 2009, 47(8): 1797-1802. DOI: 10.1016/j.fct.2009.04.026.

32.Junren C, Xiaofang X, Huiqiong Z, et al. Pharmacological Activities and Mechanisms of Hirudin and Its Derivatives-A Review[J]. Front Pharmacol, 2021, 12: 660757. DOI: 10.3389/fphar.2021.660757.

33.Chen Z, Wang G, Xie X, et al. Ginsenoside Rg5 allosterically interacts with P2RY12 and ameliorates deep venous thrombosis by counteracting neutrophil NETosis and inflammatory response[J]. Front Immunol, 2022, 13: 918476. DOI: 10.3389/fimmu.2022.918476.

34.Yin QS, Chen L, Mi RH, et al. Efficacy and safety of Danshen compound tablets in preventing thalidomide-associated thromboembolism in patients with multiple myeloma: a multicenter retrospective study[J]. Med Sci Monit, 2016, 22: 3835-3842. DOI: 10.12659/msm.900575.

35.Zhang Y, Ma C, He L, et al. Tetramethylpyrazine protects endothelial injury and antithrombosis via antioxidant and antiapoptosis in HUVECs and zebrafish[J]. Oxid Med Cell Longev, 2022: 2232365. DOI: 10.1155/2022/2232365.

36.李文悦. 乳腺癌围化疗期合并静脉血栓栓塞症(VTE)的相关因素分析及抗栓饮治疗VTE的临床疗效观察[D]. 济南: 山东中医药大学, 2023. DOI: 10.27282/d.cnki.gsdzu.2023.001032.

37.马留学, 陈治川, 李鑫, 等. 间歇充气加压联合红花注射液预防腹腔镜胃癌根治术后深静脉血栓的作用及对血清sTREM-1和骨膜蛋白的影响[J].安徽医药, 2024, 28(10): 1974-1979. [Ma LX, Chen ZC, Li X, et al. Effect of intermittent pneumatic compression combined with saffron injection on the prevention of deep vein thrombosis after laparoscopic radical surgery for gastric cancer and its effect on serum sTREM-1 and periosteal protein[J]. Anhui Medicine, 2024, 28(10): 1974-1979.] DOI: 10.3969/j. issn. 1009-6469.2024.10.014.

38.杨吉帆, 李春梅, 黄碧有, 等. 水蛭黄芪汤联合TP方案同步放化疗对局部晚期非小细胞肺癌患者DLCO、血清TGF-β1水平及复发情况的影响[J]. 中国药师, 2020, 23(7): 1363-1365, 1400. [Yang JF, Li CM, Huang BY, et al. Effects of leech and astragalus soup combined with TP regimen of synchronous radiotherapy on DLCO, serum TGF-β1 level and recurrence in patients with locally advanced non-small cell lung cancer[J]. Chinese Pharmacist, 2020, 23(7): 1363-1365, 1400.] DOI: 10.3969/j.issn.1008-049X.2020.07.026.

39.黄梅, 杨海燕, 谢丹. 三七片合三苯氧胺对绝经后乳腺癌患者子宫内膜及血液黏度影响的临床研究[J]. 新中医, 2005(8): 46-47. [Huang M, Yang HY, Xie D. Clinical study on the effects of Panax ginseng tablets and triamcinolone acetonide on endometrium and blood viscosity of postmenopausal breast cancer patients[J]. New Chinese Medicine, 2005(8): 46-47.] DOI: 10.13457/j.cnki.jncm.2005.08.023.

40.Huang B, Tang P, Liu Y, et al. Xuefu Zhuyu decoction alleviates deep vein thrombosis through inhibiting the activation of platelets and neutrophils via sirtuin 1/nuclear factor kappa-B pathway[J]. J Ethnopharmacol, 2024, 333: 118485. DOI: 10.1016/j.jep.2024.118485.

41.Feng Y, Dai L, Zhang Y, et al. Buyang Huanwu Decoction alleviates blood stasis, platelet activation, and inflammation and regulates the HMGB1/NF-κB pathway in rats with pulmonary fibrosis[J]. J Ethnopharmacol, 2024, 319(Pt 1): 117088. DOI: 10.1016/j.jep.2023.117088.

42.吴彦欣, 李如萍, 杜克群, 等. 基于“成分群协同”与“生物过程网络”解析桃红四物汤抗血栓作用机制[J].中草药, 2024, 55(21): 7365-7380. [Wu YX, Li RP, Du KX, et al. Mechanism of antithrombotic effect of Tao Hong Si Wu Tang based on "component group synergy" and "biological process network"[J]. Chinese Herbal Medicine, 2024, 55(21): 7365-7380.] DOI: 10.7501/j.issn.0253-2670.2024.21.017.

43.彭艳. 基于肿瘤细胞介导的血小板聚集(TCIPA)途径研究高原低氧环境下通窍活血汤对乳腺癌转移的作用[D]. 西宁: 青海大学, 2022. DOI: 10.27740/d.cnki.gqhdx.2022.000375.

44.Kim SH, Park HS, Hong MJ, et al. Tongqiaohuoxue decoction ameliorates obesity-induced inflammation and the prothrombotic state by regulating adiponectin and plasminogen activator inhibitor-1[J]. J Ethnopharmacol, 2016, 192: 201-209. DOI: 10.1016/j.jep.2016.07.023.

45.Liu J, Zhang J, Huang L, et al. XuefuZhuyu Tang exerts antitumor effects by inhibiting glioma cell metastasis and invasion via regulating tumor microenvironment[J]. Onco Targets Ther, 2016, 9: 3603-3612. DOI: 10.2147/OTT.S104108.

46.陈亚杰. 观察血府逐瘀汤治疗肝脏恶性肿瘤高凝状态的临床价值[J]. 临床医药文献电子杂志, 2019, 6(94): 49. [Chen YJ. Observation on the clinical value of Haifu yuyu Tang in treating hypercoagulable state of liver malignancy[J]. Electronic Journal of Clinical Medicine Literature, 2019, 6(94): 49.] DOI: 10.16281/j.cnki.jocml.2019.94.040.

47.毕俊芳, 许志会, 戢敏, 等. 补阳还五汤联合艾灸对恶性肿瘤血液高凝状态的干预研究[J]. 现代中西医结合杂志, 2022, 31(13): 1808-1812. [Bi JF, Xu ZH, Ji M, et al. Intervention of tonifying yang and returning five soup combined with moxibustion on hypercoagulable state of blood in malignant tumours[J]. Modern Journal of Integrative Medicine, 2022, 31(13): 1808-1812.] DOI: 10.3969/j.issn.1008-8849.2022.13.011.

48.么杨, 赵良. 桃红四物汤治疗晚期非小细胞肺癌血瘀证临床观察[J]. 中国中医药现代远程教育, 2021, 19(6): 90-92. [Tu  Y, Zhao L. Clinical observation on the treatment of advanced non-small cell lung cancer with blood stasis in Tao Hong Si Wu Tang[J]. Modern Distance Education of Chinese Traditional Medicine, 2021, 19(6): 90-92.] DOI: 10.3969/j.issn.1672-2779.2021.06.035.

49.李白坤, 陈诗雨, 吴晓红, 等. 桃红四物汤增强顺铂化疗对肺腺癌小鼠的抑瘤作用[J]. 中国药理学通报, 2023, 39(3): 588-593. [Li BK, Chen SY, Wu XH, et al. Enhancement of tumour-suppressive effect of cisplatin chemotherapy on lung adenocarcinoma mice by Tao Hong Si Wu Tang[J]. Chinese Journal of Pharmacology, 2023, 39(3): 588-593.] DOI: 10.12360/CPB202208064.

50.王强. 基于网络药理学探讨通窍活血汤对肿瘤介导的血小板聚集(TCIPA)的影响及作用机制研究[D]. 西宁: 青海大学, 2023. DOI: 10.27740/d.cnki.gqhdx.2023.000544.

51.陆慧, 焦建军, 马超, 等. 复原活血汤对下颌下腺瓣修复软组织缺损患者血流动力学及血清6-酮-前列腺素F1α、血栓素B2水平的影响[J]. 中国美容医学, 2022, 31(9): 26-29. [Lu  H, Jiao JJ, Ma C, et al. Effects of restorative blood-boosting soup on haemodynamics and serum 6-keto-prostaglandin F1α and thromboxane B2 levels in patients with soft tissue defects repaired by submandibular gland flap[J]. China Aesthetic Medicine, 2022, 31(9): 26-29.] DOI: 10.15909/j.cnki.cn61-1347/r.005230.

52.乔文彪, 张亚密. 复元活血汤对恶性肿瘤患者血流动力学的影响[J]. 辽宁中医杂志, 2006, (9): 1119-1120. [Qiao WB, Zhang  YM. Effect of Fuxuanxuibaiyu Tang on the haemodynamics of patients with malignant tumours[J]. Liaoning Journal of Chinese Medicine, 2006, (9): 1119-1120.] DOI: 10.13192/j.ljtcm.2006.09.67.qiaowb.036.

53.吕志伟, 潘玉真. 恶性肿瘤患者静脉血栓中医用药规律分析[J]. 中国处方药, 2023, 21(11): 155-158. [Lyu ZW, Pan  YZ. Analysis on the pattern of traditional Chinese medicine for venous thrombosis in patients with malignant tumours[J]. China Prescription Drugs, 2023, 21(11): 155-158.] DOI: 10.3969/j.issn.1671-945X.2023.11.047.

54.王华雨, 王玉涛. 中药治疗下肢深静脉血栓相关信号通路研究进展[J]. 中国中西医结合外科杂志, 2024, 30(4): 589-593. [Wang  HY, Wang YT. Progress of signalling pathways related to lower limb deep vein thrombosis treated with Chinese medicine[J]. Chinese Journal of Integrative Medicine and Surgery, 2024, 30(4): 589-593.] DOI: 10.3969/j.issn.1007-6948.2024.04.031.